AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $275K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$275K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 4 added, 1 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $56.41
- 52-wk high
- $59.30
- High
- $56.98
- 52-wk low
- $26.76
- Low
- $55.36
- Prev close
- $56.19
- Mkt cap
- $8.60B
- P/E
- 20.5x
- Volume
- 1.91M
- Fwd P/E
- 25.9x
- Beta
- 1.66
- P/S
- 10.8x
- P/B
- 14.2x
- Profit margin
- +55.2%
- Op margin
- +9.0%
- ROE
- +100.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TGTX filings
Are insiders buying or selling TG Therapeutics Inc (TGTX) stock?
Net selling: insiders sold $275K and bought $0 of TGTX stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. The largest was Charney, Laurence N (Director), who sold $275K. The latest filing was on Sep 14, 2026.
Which members of Congress have traded TGTX recently?
None. No member of Congress disclosed a TGTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this TGTX smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- DS
D.E. Shaw
$167.2M
added
- TS
Two Sigma
$84.4M
added
Sells/Trims (1)
- CI
Citadel
$34.4M
trimmed
What insiders are doing
Sells (1)
- CL
Charney Laurence N
$275K
sold
How top traders are positioned
No tracked top-trader positions in TGTX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 87.8% below what analysts expected.
Earnings per share
$0.41 expected
Reports Nov 2, 2026, in 32 days
Estimates as of Sep 29, 2026
EPS expected
$0.19 to $0.61
Revenue expected
7 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $161.7M | $192.6M | $204.9M | $240.3M |
| Cost of what it sold | $28.2M | $38.1M | $33.5M | $41.2M |
| Gross profit | $133.6M | $154.4M | $171.4M | $199.1M |
| What it spent | ||||
| Research and development | $40.9M | $41.2M | $48.4M | $95.3M |
| Sales and admin | $63.3M | $62.7M | $88.2M | $82.1M |
| Total operating expenses | $104.2M | $103.9M | $136.6M | $177.5M |
| What was left | ||||
| Operating profit | $29.4M | $50.5M | $34.8M | $21.7M |
| Interest on debt | $6.7M | $6.5M | $7.7M | $16.6M |
| Profit before tax | $25.9M | $45.1M | $20.4M | $10.2M |
| Tax | -$365.0M | $22.1M | $586.0K | $2.5M |
| Net profit | $390.9M | $23.0M | $19.8M | $7.8M |
| EBITDA | $32.7M | $51.7M | $28.1M | $21.7M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
TG Therapeutics, Inc. (TGTX) Options Chain - Yahoo Finance
NeutralSep 25TG Therapeutics Inc (TGTX) Stock Price Today: $56.12
BullishSep 24
Macro
10 macro signals shaping TGTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results